Pages that link to "Q46568257"
Jump to navigation
Jump to search
The following pages link to FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. (Q46568257):
Displaying 50 items.
- Molecular imaging in drug development (Q22122025) (← links)
- Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma (Q26771059) (← links)
- Image-guided radiation therapy in lymphoma management (Q26781339) (← links)
- Photoacoustic Imaging of Cancer Treatment Response: Early Detection of Therapeutic Effect from Thermosensitive Liposomes (Q28553001) (← links)
- 18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma (Q30654615) (← links)
- 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation (Q33606294) (← links)
- Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning (Q33608527) (← links)
- Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study (Q33627027) (← links)
- Tumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma (Q33704212) (← links)
- Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma (Q34132992) (← links)
- Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis (Q34355722) (← links)
- FDG-PET/CT in lymphoma (Q34408847) (← links)
- Positron Emission Tomography (PET) in Oncology (Q34774840) (← links)
- From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors (Q34978457) (← links)
- 18F-FDG PET/CT Imaging In Oncology (Q35006097) (← links)
- 18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports. (Q35064885) (← links)
- The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma (Q35152064) (← links)
- Use of subsequent PET/CT in diffuse large B-cell lymphoma patients in complete remission following primary therapy (Q35178725) (← links)
- Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741 (Q35584926) (← links)
- PET in lymphoma (Q35650641) (← links)
- 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell Lymphoma (Q35855599) (← links)
- Prognostic value of interim (18)F-FDG-PET in diffuse large B cell lymphoma treated with rituximab-based immune-chemotherapy: a systematic review and meta-analysis (Q35858346) (← links)
- Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin's or Non-Hodgkin's Lymphoma? (Q36038881) (← links)
- Qualitative visual trichotomous assessment improves the value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in predicting the prognosis of diffuse large B-cell lymphoma (Q36121138) (← links)
- Molecular probes for the in vivo imaging of cancer (Q36125208) (← links)
- [¹⁸F]Fluorodeoxyglucose positron emission tomography-guided therapy in metastatic adrenocortical carcinoma: an illustrative case (Q36212460) (← links)
- FDG-PET/CT based response-adapted treatment. (Q36286595) (← links)
- Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404) (Q36417808) (← links)
- Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy (Q36480167) (← links)
- Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas (Q36508858) (← links)
- Radionuclide imaging in urology (Q36531269) (← links)
- Predictive Significance of a New Prognostic Score for Patients With Diffuse Large B-Cell Lymphoma in the Interim-Positron Emission Tomography Findings (Q36581182) (← links)
- The significance of pre-therapeutic F-18-FDG PET-CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable (Q36686045) (← links)
- PET and PET/CT for response evaluation in lymphoma: current practice and developments (Q36746441) (← links)
- Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma (Q36747993) (← links)
- Functional PET imaging in cancer drug development (Q36768305) (← links)
- Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study (Q36769240) (← links)
- FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma (Q36838768) (← links)
- Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. (Q36897012) (← links)
- Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma (Q36911505) (← links)
- Overview of early response assessment in lymphoma with FDG-PET. (Q36927213) (← links)
- Is early response by (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography a predictor of long-term outcome in patients with metastatic colorectal cancer? (Q36936979) (← links)
- Whole body MRI and PET/CT in haematological malignancies. (Q36963742) (← links)
- The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era. (Q36996280) (← links)
- PET/CT in the management of haematological malignancies (Q37088536) (← links)
- State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response". (Q37144956) (← links)
- Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. (Q37240835) (← links)
- High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens (Q37321768) (← links)
- Optical imaging of Cerenkov light generation from positron-emitting radiotracers (Q37395152) (← links)
- 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. (Q37561054) (← links)